Atara Biotherapeutics, Inc. (ATRA)

Trade ATRA now with
2/28/2018 9:44:31 PM Atara Biotherapeutics Announces Pricing Of Underwritten Public Offering Of 4.29 Mln Shares At $35.00/shr
2/27/2018 7:16:34 AM Atara Biotherapeutics Posts Q4 Net Loss Of $35.3 Mln Or 41.15/share
1/19/2018 11:31:13 AM Wedbush Is Increasing Atara Biotherapeutics, Inc. (ATRA) FY18 Estimate To -3.30 From -4.17
1/19/2018 11:15:02 AM Atara Biotherapeutics Stock Price Target Raised To $70 From $47 At Canaccord
1/10/2018 8:05:57 AM Atara Receives FDA Clearance Of IND Application To Proceed With Patient Enrollment For Phase 1 Clinical Study On ATA188
1/3/2018 11:03:22 PM Atara Biotherapeutics Announces Pricing Of Public Offering Of 7 Mln Common Stock At $18.25/Shr
1/2/2018 8:18:18 AM Atara Initiates Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory EBV+PTLD
12/29/2017 6:02:23 AM Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel
12/11/2017 10:07:56 AM Atara Announces Updated Positive Interim Results From Multicenter Expanded Access Study Of Tabelecleucel
11/9/2017 8:27:26 AM Atara Biotherapeutics Q3 Net Losses $31.1 Mln Or $1.02/Shr Vs Loss $25.4 Mln Or $0.88/Shr Last Year
10/19/2017 8:03:10 AM Atara Biotherapeutics Begins 60 Patient, Global Phase 1 Clinical Study To Evaluate Allogeneic ATA188
10/16/2017 8:21:13 AM Atara Reports Abstract Publication For Two MSParis2017 Congress Presentations
9/11/2017 8:06:34 AM Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback For ATA129
9/5/2017 8:08:02 AM Atara Biotherapeutics Receives FDA Orphan Drug Designation For ATA230
6/26/2017 7:26:16 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform